| Bioactivity | Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models[1]. |
| Invitro | Anetumab ravtansine (0.01-300 nM; 4 或 24 h) 在间皮素表达细胞中表现出强大的选择性的细胞毒性，IC50 为0.72 nM，但不影响间皮素阴性或非增殖细胞[1]。Anetumab ravtansine 还诱导相邻间皮阴性肿瘤细胞的旁观者效应[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Anetumab ravtansine 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | Anetumab ravtansine (10 mg/kg; 静脉注射) 特异性定位于间皮阳性肿瘤，显示出抗肿瘤活性；并在皮下和原位异种移植模型中抑制肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1375258-01-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Golfier S, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014 Jun;13(6):1537-48. |